

## Consumer Healthcare turnover

Three months ended 31 March 2016

			Total
	£m	CER%	AR%
<b>Turnover</b>			
Wellness	925	42	44
Oral health	520	6	7
Nutrition	176	(3)	(4)
Skin health	140	93	92
Total	1,761	26	27

			Total
	£m	CER%	AR%
<b>Turnover</b>			
US	440	26	33
Europe	544	46	49
International	777	17	13
Total	1,761	26	27

**Pharmaceuticals turnover – three months ended 31 March 2016**

	Total			US			Europe			International		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
<b>Respiratory</b>	<b>1,418</b>	<b>(2)</b>	<b>1</b>	<b>633</b>	<b>2</b>	<b>9</b>	<b>348</b>	<b>(13)</b>	<b>(11)</b>	<b>437</b>	<b>1</b>	<b>1</b>
<i>Anoro Ellipta</i>	33	>100	>100	23	>100	>100	7	>100	>100	3	>100	>100
<i>Arnuity Ellipta</i>	3	>100	>100	3	>100	>100	-	-	-	-	-	-
<i>Avamys/Veramyst</i>	78	8	10	6	(17)	-	18	6	6	54	12	13
<i>Flixotide/Flovent</i>	153	(3)	-	89	1	7	25	(7)	(7)	39	(9)	(9)
<i>Incruse Ellipta</i>	22	>100	>100	19	>100	>100	3	-	-	-	-	-
<i>Nucala</i>	7	-	-	6	-	-	1	-	-	-	-	-
<i>Relvar/Breo Ellipta</i>	111	>100	>100	57	>100	>100	30	81	87	24	>100	>100
<i>Seretide/Advair</i>	753	(19)	(16)	339	(19)	(14)	226	(24)	(22)	188	(11)	(13)
<i>Ventolin</i>	179	9	11	92	10	18	31	(6)	(3)	56	16	10
Other	79	5	11	(1)	>100	<(100)	7	(12)	(13)	73	6	13
<b>Cardiovascular, metabolic and urology (CVMU)</b>	<b>184</b>	<b>(13)</b>	<b>(11)</b>	<b>59</b>	<b>(34)</b>	<b>(29)</b>	<b>78</b>	<b>13</b>	<b>16</b>	<b>47</b>	<b>(13)</b>	<b>(16)</b>
<i>Avodart</i>	132	(26)	(26)	7	(87)	(87)	77	14	17	48	(12)	(16)
<i>Eperzan/Tanzeum</i>	25	>100	>100	25	>100	>100	-	-	-	-	-	-
Other	27	4	17	27	9	17	1	-	-	(1)	>100	-
<b>Immuno-inflammation</b>	<b>65</b>	<b>3</b>	<b>8</b>	<b>59</b>	<b>-</b>	<b>7</b>	<b>5</b>	<b>-</b>	<b>25</b>	<b>1</b>	<b>&gt;100</b>	<b>-</b>
<i>Benlysta</i>	65	22	27	59	20	28	5	-	25	1	>100	-
<b>Other pharmaceuticals</b>	<b>580</b>	<b>(22)</b>	<b>(21)</b>	<b>25</b>	<b>(81)</b>	<b>(81)</b>	<b>157</b>	<b>(30)</b>	<b>(28)</b>	<b>398</b>	<b>3</b>	<b>3</b>
Dermatology	96	(12)	(12)	8	(42)	(33)	38	-	3	50	(13)	(17)
<i>Augmentin</i>	139	1	(1)	-	-	-	49	(6)	(4)	90	4	1
Other anti-bacterials	49	4	4	2	-	100	15	(6)	(6)	32	10	7
Rare diseases	93	(2)	2	11	(8)	(8)	33	-	3	49	(2)	4
Oncology	58	(73)	(73)	-	-	-	-	-	-	58	9	9
Other	145	7	7	4	(61)	(74)	22	90	99	119	8	9
<b>Established Products</b>	<b>610</b>	<b>(8)</b>	<b>(6)</b>	<b>170</b>	<b>(1)</b>	<b>4</b>	<b>126</b>	<b>(6)</b>	<b>(5)</b>	<b>314</b>	<b>(12)</b>	<b>(12)</b>
<i>Coreg</i>	32	11	19	32	11	19	-	-	-	-	-	-
<i>Hepsera</i>	15	(36)	(32)	-	-	-	-	-	35	15	(36)	(32)
<i>Imigran/Imitrex</i>	41	5	8	18	-	-	16	23	23	7	(14)	-
<i>Lamictal</i>	139	4	9	70	3	11	25	4	9	44	5	7
<i>Lovaza</i>	13	(57)	(54)	13	(57)	(54)	-	-	-	-	-	-
<i>Requip</i>	25	9	14	3	>100	>100	7	-	-	15	-	7
<i>Serevent</i>	22	(9)	(4)	10	(10)	-	9	(10)	(10)	3	-	-
<i>Seroxat/Paxil</i>	49	9	14	7	<(100)	<(100)	9	13	13	33	(11)	(6)
<i>Valtrex</i>	27	(36)	(36)	5	-	-	6	-	-	16	(48)	(48)
<i>Zeffix</i>	31	(22)	(23)	1	>100	>100	2	-	-	28	(26)	(26)
Other	216	(8)	(9)	11	-	-	52	(19)	(17)	153	(4)	(7)
	<b>2,857</b>	<b>(9)</b>	<b>(7)</b>	<b>946</b>	<b>(12)</b>	<b>(7)</b>	<b>714</b>	<b>(14)</b>	<b>(12)</b>	<b>1,197</b>	<b>(3)</b>	<b>(4)</b>
<b>HIV</b>	<b>729</b>	<b>57</b>	<b>63</b>	<b>426</b>	<b>76</b>	<b>88</b>	<b>221</b>	<b>39</b>	<b>43</b>	<b>82</b>	<b>31</b>	<b>29</b>
<i>Combivir</i>	5	(50)	(50)	(1)	<(100)	<(100)	2	(38)	(37)	4	(11)	(11)
<i>Epzicom/Kivexa</i>	154	(15)	(12)	55	(12)	(6)	70	(17)	(14)	29	(18)	(19)
<i>Lexiva/Telzir</i>	14	(13)	(13)	8	(24)	(20)	2	(39)	(37)	4	58	41
<i>Selzentry</i>	30	(3)	-	15	5	12	12	(9)	(7)	3	(13)	(17)
<i>Tivicay</i>	188	60	68	123	63	73	49	64	69	16	30	33
<i>Triumeq</i>	328	>100	>100	215	>100	>100	87	>100	>100	26	>100	>100
<i>Trizivir</i>	5	(43)	(29)	1	(46)	(43)	3	(35)	(33)	1	(73)	28
Other	5	(57)	(64)	10	(1)	6	(4)	<(100)	<(100)	(1)	(32)	(54)
<b>Pharmaceuticals</b>	<b>3,586</b>	<b>(1)</b>	<b>2</b>	<b>1,372</b>	<b>4</b>	<b>10</b>	<b>935</b>	<b>(6)</b>	<b>(3)</b>	<b>1,279</b>	<b>(2)</b>	<b>(2)</b>

**Vaccines turnover – three months ended 31 March 2016**

	Total			US			Europe			International		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
<i>Rotarix</i>	109	8	11	42	25	31	18	-	6	49	-	-
<i>Synflorix</i>	91	48	52	-	-	-	11	22	22	80	53	57
<i>Fluarix, FluLaval</i>	9	>100	>100	1	(67)	(67)	-	-	-	8	>100	>100
<i>Bexsero</i>	62	>100	>100	16	<(100)	<(100)	41	>100	>100	5	>100	>100
<i>Menveo</i>	42	>100	>100	22	>100	>100	13	>100	>100	7	>100	>100
<i>Boostrix</i>	88	29	33	36	(11)	(3)	39	>100	>100	13	17	8
<i>Infanrix, Pediarix</i>	188	(3)	1	78	6	13	91	14	18	19	(50)	(52)
Hepatitis	136	(8)	(5)	62	(8)	(3)	49	17	20	25	(37)	(34)
<i>Priorix, Priorix Tetra, Varilrix</i>	63	1	3	-	-	-	37	10	13	26	(9)	(8)
<i>Cervarix</i>	17	(39)	(39)	-	-	-	7	(30)	(30)	10	(41)	(41)
Other	77	>100	>100	5	-	25	33	>100	>100	39	>100	>100
	<b>882</b>	<b>23</b>	<b>26</b>	<b>262</b>	<b>13</b>	<b>21</b>	<b>339</b>	<b>48</b>	<b>51</b>	<b>281</b>	<b>10</b>	<b>9</b>